Alphagan 2 mg/ml kapi za oko, otopina Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

alphagan 2 mg/ml kapi za oko, otopina

abbvie d.o.o., strojarska cesta 20, zagreb, hrvatska - brimonidintartarat - kapi za oko, otopina - 2,0 mg/ml - urbroj: jedan ml otopine sadrži 2,0 mg brimonidintartarata, što odgovara 1,3 mg brimonidina

Pepaxti Europska Unija - hrvatski - EMA (European Medicines Agency)

pepaxti

oncopeptides ab - melphalan flufenamide hydrochloride - multipli mijelom - antineoplastična sredstva - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Phelinun Europska Unija - hrvatski - EMA (European Medicines Agency)

phelinun

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastična sredstva - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Melfalan Tillomed 50 mg prašak i otapalo za otopinu za injekciju/infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

melfalan tillomed 50 mg prašak i otapalo za otopinu za injekciju/infuziju

tillomed pharma gmbh, mittelstrasse 5/5a, schonefeld, njemačka - melfalanklorid - prašak i otapalo za otopinu za injekciju / infuziju - 50 mg - urbroj: jedna bočica praška sadrži 50 mg melfalana u obliku melfalanklorida.